Risk of Generalized Vitiligo is Associated with the Common 55R-94A-247H Variant Haplotype of GZMB (Encoding Granzyme B)

Tracey M. Ferrara1, Ying Jin1,3, Katherine Gowan1, Pamela R. Fain1,2,3, and Richard A. Spritz1,3

1Human Medical Genetics and Genomics Program, University of Colorado School of Medicine, Aurora, CO, USA
2Barbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine, Aurora, CO, USA
3Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA

Abstract

Generalized vitiligo (GV) is characterized by autoimmune destruction of melanocytes by skin-homing cytotoxic T-cells (CTLs) that target melanocyte autoantigens. Two recent genomewide association studies (GWAS) of GV in European-derived whites (EUR) have demonstrated genetic association with GZMB, encoding granzyme B, a marker of activated CTLs that mediates target-cell apoptosis, as well as autoantigen activation and consequent initiation and propagation of autoimmunity. Here, we describe detailed genetic analyses of the GZMB region of chromosome 14q12 to identify genetic variation potentially causal for GV, implicating two non-synonymous SNPs in strong linkage disequilibrium that comprise part of a common multi-variant high-risk haplotype, rs8192917-C—rs11539752-C (55R-94A). To identify possible uncommon deleterious variants that might “hitchhike” on the high-risk haplotype, we then carried out “next-generation” DNA re-sequencing of GZMB in 114 EUR GV patients. Overall, our findings support a direct causal role for the GZMB rs8192917-C—rs11539752-C haplotype (55R-94A) in the pathogenesis of GV.

Keywords

Vitiligo; Autoimmune disease; granzyme B; T-cells
In generalized vitiligo (GV), patches of depigmented skin and overlying hair (Picardo and Taieb, 2010) result from autoimmune destruction of melanocytes by skin-homing auto-reactive cytotoxic T-lymphocytes (CTLs) (Ogg et al., 1998). In two genome-wide association studies (GWAS) to identify GV susceptibility loci in European-derived white (EUR) patients (GWAS1, GWAS2; Jin et al., 2010, 2012) we detected association with GZMB, encoding granzyme B, a serine protease marker of activated CTLs (Sattar et al., 2003). In concert with perforin, GZMB mediates direct and caspase-mediated apoptosis of target cells (Granville, 2010; Ewen et al., 2012), as well as proteolytic cleavage of autoantigens, creating or exposing autoimmune epitopes that may initiate or propagate the autoimmune process (Darrah and Rosen, 2010).

Meta-analysis of GWAS1, GWAS2, and replication study data for SNPs genotyped in the GZMB region (Jin et al., 2012) showed greatest association with rs8192917-C ($P = 5.60 \times 10^{-9}$, OR 1.22), a common non-synonymous SNP (R55Q) that is in very strong linkage disequilibrium with two other common non-synonymous SNPs, rs11539752 (P94A; $r^2 = 0.99$) and rs2236338 (Y247H; $r^2 = 0.93$). Together, these three variants define two predominant haplotypic multi-variant GZMB polypeptide isoforms 55Q-94P-247Y (termed “QPY”) versus 55R-94A-247H (“RAH”) (McIlroy et al., 2003; Zaitsu et al., 2004). To carry out higher-resolution analysis of association of GV with SNPs in the GZMB region, we first imputed genotypes for all SNPs in the 1000 Genomes Project phase 1 integrated variant call set (June 21, 2012 release) across the 160 kb region (chr14:25045130-25204958) showing even nominal association with GV in the combined GWAS1 and GWAS2 dataset (Jin et al., 2010, 2012), from 101.5 kb upstream of GZMB through 55 kb downstream. After quality control procedures, there were 464 genotyped or imputed SNPs in 7202 total subjects (Supplementary Table S1 online). In this analysis, the most significant SNP was rs10909625 ($P = 1.03 \times 10^{-8}$), a synonymous variant at codon K80 (Table 1). To determine which SNPs in the GZMB region might be causal for GV susceptibility, we then carried out logistic regression, individually testing each of 463 SNPs conditional on rs10909625. This analysis indicated there is only one primary association signal in the GZMB region, represented by nine SNPs (Table 1) whose effects cannot be distinguished (Supplementary Table 2) due to very strong linkage disequilibrium (Supplementary Figure 1). These include rs8192917 (R55Q) and rs11539752 (P94Q); none of the other seven primary associated SNPs (rs6573910, rs6573911, rs45628336, rs113822535, rs45442494, rs1126639, rs10909625) are predicted to have functional consequences. In contrast, the associations of rs2236338 (Y247H), as well as that of another potentially functional SNP rs2273844 (stop codon within the 5′ untranslated region), were found to be secondary.

Analysis of the haplotypes defined by the three non-synonymous SNPs rs8192917-rs11539752-rs2236338 similarly indicated that principal association with GV is with the haplotype comprised of rs8192917-C—rs11539752-C. As shown in Table 2, this constitutes the higher-risk haplotype (OR 1.27; $P = 4.42 \times 10^{-8}$), compared to the haplotype that also includes the high-risk G allele of rs2236338 (OR 1.26; $P = 3.26 \times 10^{-7}$). Nevertheless, it is difficult to completely exclude any effect of rs2236338, as the haplotypes containing this SNP (C-C-G and C-C-A) are also associated with elevated risk for GV.
Genotypes of a number of uncommon (MAF < 0.01) potentially functional SNPs in the GZMB region could not be imputed with high confidence (MaCH r² < 0.3). To assess whether association of GV with GZMB might result from rare deleterious variants “hitchhiking” on the most associated haplotype of common SNPs, we therefore carried out next-generation DNA re-sequencing of a total 8.3 kb across the GZMB locus, spanning 3.2 kb upstream of the gene, the five exons and intervening sequences (with a single 783 nt gap within intervening sequence 1), to 3.1 kb downstream, in 114 unrelated EUR GV patients from GWAS1 (Jin et al., 2010). As shown in Supplementary Table S3 online, in these 228 alleles we observed a total of 41 variants. In addition to the three aforementioned common non-synonymous SNPs, we observed one additional rare non-synonymous SNP, rs185979723 (M225L) in a single heterozygote, predicted to be functionally benign. There were no nonsense, frameshift, or splice junction mutations, and no indels or other apparent rearrangements. We also observed five previously unreported variants intergenic and intronic variants, none of which were of predicted functional significance. Our findings thus suggest a major role for the common rs8192917-C—rs11539752-C—(rs2236338-G) haplotype in genetic association of GZMB with GV, with no evidence for a major contribution attributable to rare causal variants.

The mechanism by which the GZMB rs8192917-C—rs11539752-C—(rs2236338-G) haplotype increases GV risk is not yet known, as functional correlates of the corresponding 55R-94A-(247H) and 55Q-94P-(247Y) GZMB protein variant isoforms remain uncertain. Individually, the R55Q, A94P, and Y247H substitutions are each predicted to be benign (not shown); however, in silico functional predictions of individual amino acid variants are of unknown validity in the context of such multi-variant haplotypes. We speculate that the 55R-94A-247H and 55R-94A-247Y GZMB polypeptides may both increase risk of GV, the former perhaps to a greater degree than the latter. The GZMB QPY and RAH alleles exhibit similar expression, stability, and proteolytic activity of the corresponding alternative GZMB polypeptide isoforms (McIlroy et al., 2003). However, there have been conflicting claims regarding their possible differential effects on CTL effector functions. Homozygotes for the rs8192917-T (55Q) allele have been reported to express a greater proportion of GZMB-positive cells after mitogen stimulation (Girnita et al., 2009), while two studies reported reduced apoptotic induction by RAH versus QPY GZMB (McIlroy et al., 2003; Gaafar et al., 2009), and another found no difference (Sun et al., 2004). Regardless, we cannot exclude the alternative possibility that association of all GZMB coding variants with GV is secondary to LD with an as-yet unidentified causal non-coding SNP.

GZMB has not been genetically associated with other autoimmune diseases, specifically including juvenile idiopathic arthritis (Donn et al., 2008) and Behçet’s disease (Kucuksezer et al., 2009). This suggests the possibility that GZMB may be relatively specific for melanocyte-directed autoimmune susceptibility. In addition to the effector function of GZMB in target cell killing by CTLs, perhaps particularly relevant to GV may be the role played by GZMB cleavage in activating autoantigens in autoimmune disease (Darrah and Rosen, 2010). GZMB cleaves target proteins at aspartic acid residues (Odake et al., 1991), including both caspases associated with induction of apoptosis and most target cell autoantigens, potentially enhancing presentation of cryptic epitopes and leading to activation

J Invest Dermatol. Author manuscript; available in PMC 2013 December 01.
of self reactive T-cells (Sercarz et al., 1993). GZMB cleavage sites of GV melanocyte autoantigens have not yet been defined experimentally. However, in silico analysis of the principal human GV autoantigens using GRASVM 1.0 (Wee et al., 2011) predicts one high-probability GZMB cleavage site in each of TYR and TYRP1, three in TYRP2, two in SOX10, one in PMEL, and none in MC1R. These findings thus suggest that in vivo GZMB cleavage of melanocyte proteins that constitute GV autoantigens may contribute to initiation and propagation of autoimmunity directed against melanocytes.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

This work was supported by grants AR45584, AR056292, and AR056292-02S1 from the US National Institutes of Health. We thank the many vitiligo patients and family members who participated in this study.

Abbreviations

| Abbreviation | Definition |
|--------------|------------|
| CTL          | cytotoxic T-lymphocyte |
| EUR          | European-derived white |
| GV           | generalized vitiligo |
| GWAS         | genomewide association study |
| GZMB         | granzyme B |
| OR           | odds ratio |
| SNP          | simple nucleotide polymorphism |

REFERENCES

Darrah E, Rosen A. Granzyme B cleavage of autoantigens in autoimmunity. Cell Death Diff. 2010; 17:624–32.

Donn R, Ellison S, Lamb R, et al. Genetic loci contributing to hemophagocytic lymphohistiocytosis do not confer susceptibility to systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008; 58:869–74. [PubMed: 18311812]

Ewen CL, Kane KP, Bleackley RC. A quarter century of granzymes. Cell Death Diff. 2012; 19:28–35.

Giafar A, Aljurf MD, Al-Sulaiman A, et al. Defective γδ T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients. Exp Hematol. 2009; 37:838–48. [PubMed: 19446661]

Girmita DM, Webber SA, Brooks MM, et al. Genotypic variation and phenotypic characterization of granzyme B gene polymorphisms. Transplantation. 2009; 87:1801–6. [PubMed: 19543056]

Granville DJ. Granzymes in disease: bench to bedside. Cell Death Diff. 2010; 17:565–6.

Jin Y, Birlea SA, Fain PR, et al. Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. New Engl J Med. 2010; 362:1686–97. [PubMed: 20410501]

Jin Y, Birlea SA, Fain PR, et al. Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet. 2012; 44:676–80. [PubMed: 22561518]

Kukuksezer UC, Duyuzm Tozkier J, Gül A, et al. No association of granzyme B polymorphism with Behçet’s disease. Clin Exp Rheumatol. 2009; 27(2 Suppl 53):S102.
McIlroy D, Cartron P-F, Tuffery P, et al. A triple-mutated allele of granzyme B incapable of inducing apoptosis. Proc Natl Acad Sci USA. 2003; 100:2562–7. [PubMed: 12594335]

Odake S, Kam CM, Narasimhan L, et al. Human and murine cytotoxic T lymphocyte serine proteases: subsite mapping with peptide thioester substrates and inhibition of enzyme activity and cytolysis by isocoumarins. Biochem. 1991; 30:2217–27. [PubMed: 1998680]

Ogg GS, Dunbar PR, Romero P, et al. High frequency of skin homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med. 1998; 188:1203–8. [PubMed: 9743539]

Picardo, M.; Taïeb, A., editors. Vitiligo. Springer; New York: 2010.

Sattar R, Ali SA, Abbasi A. Bioinformatics of granzymes: sequence comparison and structural studies on granzyme family by homology modeling. Biochem Biophys Res Comm. 2003; 308:726–35. [PubMed: 12927779]

Sercarz EE, Lehmann PV, Ametani A, et al. Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol. 1993; 11:729–66. [PubMed: 7682817]

Sun J, Bird CH, Thia KY, et al. Granzyme B encoded by the commonly occurring human RAH allele retains pro-apoptotic activity. J Biol Chem. 2004; 279:16907–11. [PubMed: 14752093]

Zaitsu M, Yamamoto K, Ishii E, et al. High frequency of QPY allele and linkage disequilibrium of granzyme-B in Epstein-Barr-virus-associated hemophagocytic lymphohistiocytosis. Tissue Antigens. 2004; 64:611–5. [PubMed: 15496206]
### Table 1

Association of GV with SNPs in the *GZMB* region of chromosome 14q12

| SNP      | nt   | A1 | A2 | A1 freq | GWAS1 p   | GWAS1 OR | GWAS2 p   | GWAS2 OR | CMH p | CMH OR | CMH L95 | CMH U95 | Call type | Function   |
|----------|------|----|----|---------|------------|----------|------------|----------|--------|--------|---------|---------|-----------|------------|
| rs2236338| 25100282 | G  | A  | 0.24   | 4.18 × 10^{-5} | 1.25     | 2.96 × 10^{-2} | 1.20     | 3.32 × 10^{-6} | 1.23 | 1.13 | 1.35 | genotyped | Y247H |
| rs6573910| 25100882 | T  | C  | 0.25   | 3.15 × 10^{-6} | 1.28     | 1.82 × 10^{-2} | 1.22     | 1.84 × 10^{-7} | 1.27 | 1.16 | 1.38 | imputed |
| rs6573911| 25100933 | T  | C  | 0.25   | 3.15 × 10^{-6} | 1.28     | 1.82 × 10^{-2} | 1.22     | 1.84 × 10^{-7} | 1.27 | 1.16 | 1.38 | imputed |
| rs45628336| 25101440 | T  | C  | 0.24   | 1.48 × 10^{-6} | 1.30     | 1.88 × 10^{-6} | 1.22     | 9.69 × 10^{-8} | 1.27 | 1.17 | 1.39 | imputed |
| rs113822535| 25101465 | T  | G  | 0.24   | 9.11 × 10^{-7} | 1.30     | 2.08 × 10^{-2} | 1.22     | 6.60 × 10^{-8} | 1.28 | 1.17 | 1.40 | imputed |
| rs45442494| 25101475 | T  | G  | 0.24   | 6.20 × 10^{-7} | 1.31     | 1.84 × 10^{-5} | 1.22     | 4.01 × 10^{-8} | 1.28 | 1.17 | 1.40 | imputed |
| rs1126639| 25101548 | A  | G  | 0.24   | 2.38 × 10^{-6} | 1.29     | 2.19 × 10^{-2} | 1.21     | 1.74 × 10^{-7} | 1.27 | 1.16 | 1.38 | imputed |
| rs11539752| 25101589 | C  | G  | 0.24   | 2.98 × 10^{-6} | 1.29     | 2.32 × 10^{-2} | 1.21     | 2.27 × 10^{-7} | 1.26 | 1.16 | 1.38 | imputed | P94A |
| rs10909625| 25101629 | C  | T  | 0.24   | 9.15 × 10^{-7} | 1.31     | 1.22 × 10^{-2} | 1.24     | 3.92 × 10^{-8} | 1.28 | 1.17 | 1.40 | imputed |
| rs8192917| 25102160 | C  | T  | 0.25   | 2.83 × 10^{-6} | 1.29     | 2.39 × 10^{-2} | 1.21     | 2.25 × 10^{-7} | 1.26 | 1.16 | 1.38 | genotyped | R55Q |
| rs2273844| 25103414 | A  | G  | 0.24   | 4.81 × 10^{-6} | 1.28     | 3.00 × 10^{-2} | 1.20     | 4.78 × 10^{-7} | 1.26 | 1.15 | 1.37 | genotyped | Stop gained |

Data are shown for nine genotyped or imputed SNPs (Supplementary Table S1) whose effects could not be distinguished by logistic regression analysis, due to linkage disequilibrium (Supplementary Table S2), as well as for two additional potential functional SNPs, rs2236338 (Y247H) and rs2273844 (stop codon within 5’ untranslated region), nt, nucleotide position on chromosome 14 (alleles denoted on forward strand).

A1, effect allele (here, high-risk)
A2, reference allele
A1 freq, A1 allele frequency in summary 7202 GV cases and controls
GWAS 1, data from 1388 GV cases and 2586 controls (Jin et al., 2010)
GWAS2, data from 418 GV cases and 2810 controls (Jin et al., 2012)
OR, odds ratio
CMH, Cochran-Mantel-Haenszel meta-analysis
L95, lower limit of 95% confidence interval; U95, upper limit of 95% confidence interval. Note that subject quality control was carried out using the combined GWAS1+GWAS2 dataset, and subjects in GWAS1 who were related to subjects in GWAS2 (pi-hat > 0.05) were removed. Cochran-Mantel-Haenszel analysis here does not include replication studies of GWAS1 or GWAS2, which could not be imputed therefore, P-values shown here for some SNPs are less significant here than reported in Jin et al., 2012 because of lower sample size.
Table 2

Analysis of haplotypes of *GZMB* non-synonymous SNPs rs8192917 (R55Q), rs11539752 (P94A), and rs2236338 (Y247H)

| SNP Haplotype | Amino Acid | F_A | F_U | P       | OR |
|---------------|------------|-----|-----|---------|----|
| **3-SNP Haplotypes (rs8192917-rs11539752-rs2236338)** |            |     |     |         |    |
| TGA           | 55Q-94P-227Y | 0.716 | 0.760 | 1.08E-07 | ref |
| CCG           | 55R-94A-247H | 0.270 | 0.228 | 3.26E-07 | 1.26 |
| CCA           | 55-R-94A-247Y | 0.009 | 0.005 | 0.02587 | 1.69 |
| TGG           | 55Q-94P-247H | 0.006 | 0.006 | 0.5314 | 0.9 |
| **2-SNP Haplotypes (rs8192917-rs11539752)** |            |     |     |         |    |
| TG            | 55Q-94P     | 0.7211 | 0.7663 | 4.42E-08 | ref |
| CC            | 55R-94A     | 0.2789 | 0.2337 | 4.42E-08 | 1.27 |

*P* values compare the frequency of the designated haplotype with all other haplotypes in cases versus controls. F_A, frequency in cases. F_U, frequency in controls. OR, odds ratio compared to the reference (ref) haplotype.